Dynamic Metabolic Changes during the First 3 Months after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy

Dynamic Metabolic Changes during the First 3 Months after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy

Objective. To elucidate the time course of tumor metabolism during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) in patients with refractory malignant lymphoma. Materials and Methods. Seven patients with recurrent follicular lymphoma underwent FDG-PET imaging before and...

Full description

Bibliographic Details
Main Authors:	Miwako Takahashi, Toshimitsu Momose, Keitaro Koyama, Motoshi Ichikawa, Mineo Kurokawa, Kuni Ohtomo
Format:	Article
Language:	English
Published:	Hindawi Limited 2014-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1155/2014/368947

Similar Items

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
by: McKinney MS, et al.
Published: (2014-08-01)

Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
by: Martina Lehnert, et al.
Published: (2009-07-01)

Bulky Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan
by: Shinobu Tamura, et al.
Published: (2013-01-01)

Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA)
by: Sarbajit Mukherjee, et al.
Published: (2018-09-01)

RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution
by: Marcio Miguel Andrade Campos, et al.
Published: (2012-01-01)

Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin&rsquo;s lymphoma
by: Christos Emmanouilides
Published: (2009-10-01)

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
by: Michael A. Lane, et al.
Published: (2015-01-01)

Nouvelles modalités (consolidation, fractionnement) de radioimmunothérapie par 90Y-ibritumomab tiuxetan ("Zevalin") en traitement de première ligne des lymphomes malin non hodgkinien de type folliculaire: efficacité, toxicité et approche dosimétrique personnalisée
by: Morschhauser, Franck
Published: (2008)

FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by <sup>90</sup>yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases
by: Assisi Daniela, et al.
Published: (2011-02-01)

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (<sup>111</sup>In)/Yttrium 90 (<sup>90</sup>Y) Ibritumomab Tiuxetan (Zevalin<sup>®</sup>) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
by: Richard L. Wahl, et al.
Published: (2021-06-01)

Resistance to ibritumomab in lymphoma
by: Lalit Kumar
Published: (2020-01-01)

Single-Dose Cisplatin Pre-Treatment Enhances Efficacy of ROBO1-Targeted Radioimmunotherapy
by: Kentaro Fujiwara, et al.
Published: (2020-10-01)

Radioimmunotherapy of lymphoma
by: Goldsmith Stanley J.
Published: (2012-01-01)

Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
by: Dhanusha Sabanathan, et al.
Published: (2021-10-01)

Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy.
by: Peter Kletting, et al.
Published: (2015-01-01)

RADIOIMMUNOTHERAPY IN THE TREATMENT OF MALIGNANCIES
by: V. I. Chernov, et al.
Published: (2016-07-01)

Radiopharmaceuticals in immunoscintigraphy and radioimmunotherapy
by: René Leyva Montaña
Published: (2012-07-01)

Pretargeted Molecular Imaging and Radioimmunotherapy
by: David M. Goldenberg, Chien-Hsing Chang, Edmund A. Rossi, William J, McBride, Robert M. Sharkey
Published: (2012-01-01)

Improvement of radioimmunotherapy using pretargeting
by: Eric eFrampas, et al.
Published: (2013-06-01)

Experimental radioimmunotherapy and effector mechanisms
by: Eriksson, David
Published: (2006)

Radioimmunotherapy - Translational Opportunities and Challenges
Published: (2020)

Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.
by: Johnnie J Orozco, et al.
Published: (2014-01-01)

Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
by: Sofia H L Frost, et al.
Published: (2015-01-01)

Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma
by: Andrew D. Ludwig, et al.
Published: (2019-01-01)

Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors
by: Andrea Cimini, et al.
Published: (2020-05-01)

Editorial: Radioimmunotherapy—Translational Opportunities and Challenges
by: Udo S. Gaipl, et al.
Published: (2020-02-01)

Combination Radioimmunotherapy Strategies for Solid Tumors
by: Javeria Zaheer, et al.
Published: (2019-11-01)

Optimization of radioimmunotherapy for non-Hodgkin's lymphoma
by: Du, Yong
Published: (2005)

Fractionated radioimmunotherapy of non-Hodgkin's lymphoma
by: Bayne, Michael Christopher
Published: (2005)

A case of recurrent depressive disorder presenting with Alice in Wonderland syndrome: psychopathology and pre- and post-treatment FDG-PET findings
by: Tatsushi Yokoyama, et al.
Published: (2017-04-01)

Experimental and clinical approaches to a radioimmunotherapy in o
by: E. V. Abakushina, et al.
Published: (2016-02-01)

Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma
by: Caroline eBodet-Milin, et al.
Published: (2013-07-01)

Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy
by: Licia Uccelli, et al.
Published: (2017-01-01)

Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
by: Ekaterina Dadachova, et al.
Published: (2011-01-01)

Radiation dosimetry of radioimmunotherapy antibodies conjugated with ��Y
by: Al-Hussan, Khalid A.I. Eleissa
Published: (2012)

Antibody conjugate radioimmunotherapy of superficial bladder cancer
by: Alan Perkins, et al.
Published: (2002-09-01)

Radioimmunotherapy: future prospects from the perspective of brachytherapy
by: Maximilian Fleischmann, et al.
Published: (2021-08-01)

Improved mehtods and reagents for pretargeted radioimmunotherapy of cancer
by: Zajic, Stefan C
Published: (2007)

Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
by: Aya Sugyo, et al.
Published: (2015-01-01)

Analisi costi-efficacia di 90Y-ibritumomab tiuxetano (Zevalin®) vs. terapie attualmente disponibili nel trattamento dei pazienti affetti da Linfoma Non-Hodgkin (LNH) refrattario o recidivato
by: Carlo Lazzaro, et al.
Published: (2005-12-01)

Cannot write session to /tmp/vufind_sessions/sess_npi2ubj5u12rdhjio07ff3b2e0